Amazon Web Services (AWS) announced that Moderna Inc., a biotechnology company has selected AWS as its preferred cloud provider and its standard for analytics and machine learning workloads. Moderna is leveraging its mRNA platform and manufacturing facility with the AWS-powered research engine, delivered its first clinical batch of vaccine candidate (mRNA-1273) against COVID-19 to the NIH for the Phase 1 trial 42 days after the initial sequencing of the virus. By AWS, Moderna is able to accelerate its design research experiments and uncover new insights, automate its laboratory and manufacturing processes to enhance its drug discovery pipeline more easily.
Matt Garman, Vice President, Sales and Marketing at AWS said, “Running on AWS, Moderna has the agility to continuously refine its research, development, and manufacturing. Moderna is relying on the proven performance and scale of the world’s leading cloud to innovate and develop drug and vaccine candidates on timelines that may have been impossible even just a few years ago”.
Researching and developing new drugs is expensive process. Scientists conduct years of basic research to understand how new diseases act at a molecular level in the human body and need to screen thousands of different molecular compounds (the basis for many drugs) to assess their safety and efficiency. After they narrow down the pipeline, researchers perform multiple rounds of testing in the laboratory before advancing the most promising drug candidates for further study. Moderna is managing these challenges, leveraging AWS services to simplify the research and manufacturing of new class of drugs, based on mRNA.
Moderna has invented technologies and methods that run on AWS to create mRNA constructs. This allows Moderna to experiment on virtually any mRNA sequence, easily shifting between research priorities, without investing in new technology.
Moderna runs all of its SAP S/4HANA workloads on AWS, including manufacturing, accounting, and inventory management, which enables the company to achieve greater efficiency and visibility across its operations. AWS also powers Moderna’s highly automated production facility with its IoT services to connect the manufacturing instruments, robotics, and other critical systems.
Stéphane Bancel, Moderna’s Chief Executive Officer said, “The science behind mRNA medicines is advancing at a rapid pace, and building Moderna’s technology platform on AWS gives our scientists the insights, agility, and security they need to continue to lead in the industry. With AWS, our researchers have the ability to quickly design and execute research experiments and rapidly uncover new insights to get potentially life-saving treatments into production faster. AWS’s breadth and depth of services are supporting our mission to create a new generation of medicines for patients and are instrumental in our quest to develop a vaccine for COVID-19 and other life-threatening diseases”.
You can read more details here.